**Background of DNM2 Antibody**
DNM2 (Dynamin-2) is a ubiquitously expressed GTPase involved in membrane remodeling processes, including endocytosis, intracellular vesicle trafficking, and organelle division. It plays a critical role in clathrin-mediated endocytosis by constricting and severing membrane necks during vesicle formation. DNM2 also regulates cytoskeletal dynamics and autophagy. Dysregulation or mutations in *DNM2* are linked to several diseases, such as centronuclear myopathy, Charcot-Marie-Tooth neuropathy, and cancers, where altered membrane trafficking contributes to pathogenesis.
DNM2 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate DNM2's role in cellular processes or disease mechanisms. Specific antibodies target distinct DNM2 isoforms or post-translational modifications, enabling precise analysis. For example, research utilizing DNM2 antibodies has revealed its interaction with proteins like amphiphysin and microtubules, as well as its phosphorylation-dependent regulatory mechanisms.
Additionally, DNM2 antibodies aid in diagnosing genetic disorders caused by *DNM2* mutations. In therapeutic contexts, they help evaluate DNM2-targeting strategies, such as inhibitory peptides or small molecules, to modulate endocytosis in cancer or neurological conditions. Overall, DNM2 antibodies are pivotal in advancing both basic research and clinical applications related to membrane dynamics and associated pathologies.